Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 March 2021 | Story Ruan Bruwer | Photo Netball South Africa
Defender Refiloe Nketsa is one of four Kovsies chosen for the South African U21 netball team.

With no less than four Kovsies in the South African Under 21 netball team, the near future for this sport at the University of the Free State (UFS) is certainly on the bright side.

Chanel Vrey, Refiloe Nketsa, Rolene Streutker, and Boitumelo Mahloko will be in action for the Baby Proteas, as the team is known, in a challenge series. The team will battle the President’s XII (a South African A team) and Uganda from 25 March in Cape Town. 

They all played for the Free State senior side last year. Vrey and Streutker also played for the Baby Proteas against international competition in 2019.

Mahloko – a former Kovsie – and Nketsa have also represented South Africa at junior level in the past. They were team members in the national U16 team in 2017, and a year later Mahloko made the U20 team and Nketsa the SA U18 team.

Khanyisa Chawane will also be in action in the series, playing for the Proteas, while former Kovsie captain Alicia Puren has been chosen for the President’s XII.

Meanwhile, two hockey players, Saré Laubscher and Zimkhitha Weston, have been picked for the South African U21 women’s hockey team. They would have participated in the African qualifying tournament in Ghana at the end of March. This tournament has, however, been postponed to January 2022. 

This is the third consecutive year that Laubscher has made the team. Weston, a former Kovsie, played for South Africa at the 2018 Youth Olympic Games in Argentina.

The African Hockey Qualifier serves as qualification for the Junior World Cup, which is scheduled for December in Potchefstroom. South Africa has already qualified as hosts for the Junior World Cup, but the African crown is up for grabs in Ghana. 

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept